Alto Neuroscience (ANRO) Profit After Tax (2023 - 2026)
Alto Neuroscience (ANRO) posted Profit After Tax of -$26.2 million for Q1 2026, down 328062.5% sequentially from $8000.0 in Q4 2025, and down 22914.78% YoY from N/an in Q1 2025.
Alto Neuroscience (ANRO) Profit After Tax (2023 - 2026) Analysis & Trends
Alto Neuroscience has reported Profit After Tax for 4 years, with the latest figure at -$26.2 million in Q1 2026.
- Quarterly Profit After Tax fell 22914.78% year-over-year to -$26.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$58.1 million (down 530.17% YoY) and the FY2025 annual result came in at $123000.0, up 659.09% from the prior year.
- Profit After Tax fell to -$26.2 million in Q1 2026 per ANRO's latest filing, from $8000.0 in the prior quarter.
- Over five years, Profit After Tax peaked at $46.2 million in Q4 2024 and troughed at -$26.2 million in Q1 2026.
- A 4-year average of -$5.7 million and a median of -$8.7 million in 2023 frame the typical range for Profit After Tax.
- The widest YoY moves for Profit After Tax: up 660014.29% in 2024, down 167730.0% in 2024.
- Over 4 years, Profit After Tax stood at $7000.0 in 2023, then jumped by 660014.29% to $46.2 million in 2024, then tumbled by 99.98% to $8000.0 in 2025, then tumbled by 328062.5% to -$26.2 million in 2026.
- According to Business Quant data, Profit After Tax over the past three periods registered -$26.2 million, $8000.0, and -$14.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Alto Neuroscience | 1.13 Bn | 1.13 Bn | - | -27.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -27.64 Mn |
| Mar 31, 2026 | -26.24 Mn |
| Dec 31, 2025 | 8,000.00 |
| Sep 30, 2025 | -14.18 Mn |
| Jun 30, 2025 | -17.71 Mn |
| Mar 31, 2025 | 115,000.00 |
| Dec 31, 2024 | 46.21 Mn |
| Sep 30, 2024 | -16.78 Mn |
| Jun 30, 2024 | -16.03 Mn |
| Mar 31, 2024 | -13.42 Mn |
| Dec 31, 2023 | 7,000.00 |
| Sep 30, 2023 | -10,000.00 |
| Jun 30, 2023 | -8.66 Mn |
| Mar 31, 2023 | -7.28 Mn |